S. X. Huang, M. C. Jaurand, D. W. Kamp, J. Whysner, and T. K. Hei, Role of mutagenicity in asbestos fiberinduced carcinogenicity and other diseases, J Toxicol Environ Health B Crit Rev, vol.14, issue.1-4, pp.179-245, 2011.

L. Mutti, T. Peikert, B. W. Robinson, A. Scherpereel, A. S. Tsao et al.,

J. Jablons, F. R. Wiens, H. Hirsch, M. Yang, A. Carbone et al., State of the Art: Concise Review Scientific Advances and New Frontiers in Mesothelioma Therapeutics, J Thorac Oncol, 2018.

M. C. Jaurand and D. Jean, Biomolecular Pathways and Malignant Pleural Mesothelioma
URL : https://hal.archives-ouvertes.fr/inserm-02479956

. Mineo, Malignant Pleural Mesothelioma: Present Status and Future Directions, pp.169-192, 2016.

R. Bueno, E. W. Stawiski, L. D. Goldstein, S. Durinck, A. De-rienzo et al.,

B. S. Nguyen, L. R. Jaiswal, D. Chirieac, N. Sciaranghella, C. E. Dao et al.,

D. J. Wu, F. J. Sugarbaker, W. G. De-sauvage, S. Richards, and . Seshagiri, Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations, Nature genetics, vol.48, issue.4, pp.407-423, 2016.

A. De-reynies, M. C. Jaurand, A. Renier, G. Couchy, I. Hysi et al.,

P. Copin, A. Hofman, P. Cazes, S. Andujar, F. Imbeaud et al.,

D. Zucman-rossi and . Jean, Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition, Clin Cancer Res, vol.20, issue.5, pp.1323-1357, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-02478599

R. Tranchant, L. Quetel, A. Tallet, C. Meiller, A. Renier et al.,

J. Barthes, M. C. Zucman-rossi, D. Jaurand, and . Jean, Co-occurring mutations of tumor suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma, Clin Cancer Res, vol.23, issue.12, pp.3191-3202, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-02478604

G. Zalcman, J. Mazieres, J. Margery, L. Greillier, C. Audigier-valette et al.,

F. Lebitasy, C. Morin, J. J. Creveuil, A. Parienti, and . Scherpereel, French Cooperative Thoracic Intergroup, Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, Lancet, vol.387, pp.1405-1419, 2016.

A. Guazzelli, E. Bakker, K. Tian, C. Demonacos, M. Krstic-demonacos et al., Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma, Expert Opin Investig Drugs, vol.26, issue.8, pp.933-944, 2017.

N. P. Tobin, T. Foukakis, L. De-petris, and J. Bergh, The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer, Journal of Internal Medicine, vol.278, issue.6, pp.545-570, 2015.

T. R. Samatov, V. V. Galatenko, A. Block, M. Y. Shkurnikov, A. G. Tonevitsky et al., Novel biomarkers in cancer: The whole is greater than the sum of its parts, Seminars in Cancer Biology, vol.45, pp.50-57, 2017.

P. Andujar, J. C. Pairon, A. Renier, A. Descatha, I. Hysi et al.,

B. Blons, C. Clin, D. Danel, F. Debrosse, B. Galateau-salle et al.,

M. Barthes, I. Letourneux, J. F. Monnet, P. Regnard, J. Validire et al., Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma, Mutagenesis, vol.28, issue.3, pp.323-354, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-02478590

A. Tallet, J. C. Nault, A. Renier, I. Hysi, F. Galateau-salle et al.,

F. L. Andujar, J. Pimpec-barthes, M. C. Zucman-rossi, D. Jaurand, and . Jean, Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma, Oncogene, vol.33, issue.28, pp.3748-52, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-02478602

D. Jean, E. Thomas, E. Manie, A. Renier, A. De-reynies et al.,

M. Galateau-salle, J. Giovannini, M. H. Zucman-rossi, M. C. Stern, and . Jaurand, Syntenic Relationships between Genomic Profiles of Fiber-Induced Murine and Human Malignant Mesothelioma, Am J Pathol, vol.178, issue.2, pp.881-94, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00531343

L. Zeng, A. Buard, I. Monnet, C. Boutin, J. Fleury et al.,

. Jaurand, In vitro effects of recombinant human interferon gamma on human mesothelioma cell lines, Int J Cancer, vol.55, issue.3, pp.515-535, 1993.

S. Rondeau, S. Vacher, L. Koning, A. Briaux, A. Schnitzler et al., ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels, British Journal of Cancer, vol.112, issue.6, pp.1059-1066, 2015.

I. M. Shapiro, V. N. Kolev, C. M. Vidal, Y. Kadariya, J. E. Ring et al.,

A. I. Padval, Q. Mcclatchey, J. R. Xu, J. A. Testa, and . Pachter, Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship, Science translational medicine, vol.6, issue.237, pp.237-68, 2014.

A. Scherpereel, F. Wallyn, S. M. Albelda, and C. Munck, Novel therapies for malignant pleural mesothelioma, Lancet Oncol, vol.19, issue.3, pp.161-172, 2018.

W. Yang, J. Soares, P. Greninger, E. J. Edelman, H. Lightfoot et al.,

M. J. Mcdermott and . Garnett, Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells, Nucleic Acids Res, vol.41, pp.955-61, 2013.

E. Suzuki, S. Kim, H. Cheung, M. J. Corbley, X. Zhang et al.,

L. E. Albelda and . Ling, A Novel Small-Molecule Inhibitor of Transforming Growth Factor ? Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth In vivo and Prevents Tumor Recurrence after Surgical Resection, Cancer Research, vol.67, issue.5, pp.2351-2359, 2007.

D. Jean, J. Daubriac, F. L. Pimpec-barthes, F. Galateau-salle, and M. C. Jaurand, Molecular changes in mesothelioma with an impact on prognosis and treatment, Archives of pathology & laboratory medicine, vol.136, issue.3, pp.277-93, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-02478588

H. Cho, S. Matsumoto, Y. Fujita, A. Kuroda, T. Menju et al., Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in

. Malignant-pleural-mesothelioma, Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer, vol.12, issue.3, pp.477-490, 2017.

C. W. Menges, Y. Chen, B. T. Mossman, J. Chernoff, A. T. Yeung et al., A Phosphotyrosine Proteomic Screen Identifies Multiple Tyrosine Kinase Signaling Pathways Aberrantly Activated in Malignant Mesothelioma, Genes Cancer, vol.1, issue.5, pp.493-505, 2010.

V. Monica, M. Lo-iacono, E. Bracco, S. Busso, L. D. Blasio et al., Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines, Oncotarget, vol.7, issue.47, pp.76577-76589, 2016.

L. A. Marek, T. K. Hinz, A. Mässenhausen, K. A. Olszewski, E. K. Kleczko et al.,

R. A. Weiser-evans, H. Nemenoff, A. Hoffmann, J. M. Warth, S. Gozgit et al., Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma, Molecular cancer research: MCR, vol.12, issue.10, pp.1460-1469, 2014.

K. Schelch, M. A. Hoda, T. Klikovits, J. Münzker, B. Ghanim et al.,

B. Setinek, M. Dome, C. Filipits, P. Pirker, E. Heffeter et al.,

B. Holzmann, B. Grasl-kraupp, W. Marian, W. Klepetko, B. Berger et al., Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio-and chemotherapy, American journal of respiratory and critical care medicine, vol.190, issue.7, pp.763-772, 2014.

K. Schelch, M. B. Kirschner, M. Williams, Y. Y. Cheng, N. Van-zandwijk et al., A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma, Molecular Oncology, vol.12, issue.1, pp.58-73, 2018.

E. Giovannetti, P. A. Zucali, Y. G. Assaraf, L. G. Leon, K. Smid et al.,

E. Gianoncelli, M. Lorenzi, A. Roncalli, G. J. Santoro, and . Peters, Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin, British Journal of Cancer, vol.105, issue.10, pp.1542-1553, 2011.

M. Sayan, A. Shukla, M. B. Macpherson, S. L. Macura, J. M. Hillegass et al., Extracellular signal-regulated kinase 5 and cyclic AMP response element binding protein are novel pathways inhibited by vandetanib (ZD6474) and doxorubicin in mesotheliomas, American journal of respiratory cell and molecular biology, vol.51, issue.5, pp.595-603, 2014.

V. Laszlo, Z. Valko, I. Kovacs, J. Ozsvar, M. A. Hoda et al.,

T. H. Stiglbauer, M. Helbich, J. Gröger, W. Tovari, C. Klepetko et al., Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In Vivo, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 2018.

J. Vaquero, T. H. Nguyen-ho-bouldoires, A. Claperon, and L. Fouassier, Role of the PDZ-scaffold protein NHERF1/EBP50 in cancer biology: from signaling regulation to clinical relevance, Oncogene, vol.36, issue.22, pp.3067-3079, 2017.

G. Bulut, S. Hong, K. Chen, E. M. Beauchamp, S. Rahim et al.,

H. Dakshanamurthy, I. Lee, J. A. Daar, C. Toretsky, A. Khanna et al., Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells, Oncogene, vol.31, issue.3, pp.269-281, 2012.

T. Kato, T. Sato, K. Yokoi, and Y. Sekido, E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells, Oncogene, vol.36, issue.39, pp.5522-5531, 2017.

Y. Liu-chittenden, B. Huang, J. S. Shim, Q. Chen, S. J. Lee et al., Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP, Genes Dev, vol.26, issue.12, pp.1300-1305, 2012.

T. Mizuno, H. Murakami, M. Fujii, F. Ishiguro, I. Tanaka et al.,

H. Yokoi, Y. Osada, and . Sekido, YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes, Oncogene, vol.31, issue.49, pp.5117-5139, 2012.

J. W. Miller, U. Schmidt-erfurth, M. Sickenberg, C. J. Pournaras, H. Laqua et al.,

B. Zografos, G. Piguet, A. M. Donati, R. Lane, H. Birngruber et al.,

M. Gray, N. M. Fsadni, E. S. Bressler, and . Gragoudas, Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study, Arch Ophthalmol, vol.117, issue.9, pp.1161-73, 1999.

W. Q. Zhang, Y. Y. Dai, P. C. Hsu, H. Wang, L. Cheng et al., Targeting YAP in malignant pleural mesothelioma, J Cell Mol Med, vol.21, issue.11, pp.2663-2676, 2017.

X. Zhang, N. Tang, A. K. Rishi, H. I. Pass, and A. Wali, Methylation profile landscape in mesothelioma: possible implications in early detection, disease progression, and therapeutic options, Methods Mol Biol, vol.1238, pp.235-282, 2015.

V. R. Dasari, V. Mazack, W. Feng, J. Nash, D. J. Carey et al., Verteporfin exhibits YAPindependent anti-proliferative and cytotoxic effects in endometrial cancer cells, Oncotarget, vol.8, issue.17, pp.28628-28640, 2017.

C. Zeltz, S. Brézillon, J. Käpylä, J. A. Eble, H. Bobichon et al., Lumican inhibits cell migration through ?2?1 integrin, Experimental Cell Research, vol.316, issue.17, pp.2922-2931, 2010.

X. Wang, Q. Zhou, Z. Yu, X. Wu, X. Chen et al., Cancer-associated fibroblast-derived Lumican promotes gastric cancer progression via the integrin ?1-FAK signaling pathway, International Journal of Cancer, vol.141, issue.5, pp.998-1010, 2017.

Y. Miyata, M. Akashi, and E. Nishida, Molecular cloning and characterization of a novel member of the MAP kinase superfamily, Genes to Cells: Devoted to Molecular & Cellular Mechanisms, vol.4, issue.5, pp.299-309, 1999.